Delivera Pharma Secures Tens of Millions in Angel Funding to Advance Globally First-in-Class Drug Delivery Platforms Addressing Critical Clinical Needs

VCBeat has learned that Beijing Delifurui Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Delifurui”) recently announced the completion of its angel financing round, amounting to tens of millions of yuan. This round was exclusively invested by HY Asset Management Co., Ltd. The funds will be primarily used for production applications of existing R&D products, clinical trials, expansion of the professional team, and production of marketed products.

As an emerging innovator in the field of drug delivery systems in China, Beijing Delifurui Pharmaceutical Technology Co., Ltd. has been dedicated to the research and development as well as industrialization of innovative drug delivery systems since its establishment. The company’s R&D efforts are closely aligned with unmet clinical needs, with a pipeline that broadly covers key therapeutic areas including oncology, cardiovascular and cerebrovascular diseases, antifungal treatments, and postoperative pain management. By keeping pace with international advancements and gaining deep insights into clinical medication requirements, Delifurui is committed to developing drug delivery systems with original innovation.

Leveraging the R&D team led by Academician Zhang Qiang of Peking University, the company has filled gaps in drug delivery technologies with two globally pioneering platforms—the Self-Emulsifying Delivery Technology Platform for Injectable Poorly Soluble Drugs and the Nanodelivery Technology Platform for Oral Poorly Soluble Drugs—providing solutions to meet critical clinical needs.

Drug delivery systems demonstrate significant market potential and broad application prospects in areas such as biologics, gene therapy, and traditional Chinese medicine formulations. The transition of these two technologies from the laboratory to industrialization marks a major advancement in the field of drug delivery.

Acta Pharmaceutica Sinica points out that 40% of globally marketed drugs are poorly soluble, and this proportion reaches as high as 90% among candidate drugs under development. Today, drug delivery system technology has become a core breakthrough for enhancing drug efficacy and reducing toxic side effects.

Established by Beijing Delifurui Pharmaceutical Technology Co., Ltd.“Self-Emulsifying Delivery Technology Platform for Poorly Soluble Injectable Drugs”and"Nano-Delivery Technology Platform for Oral Poorly Soluble Drugs"As a globally pioneering technology, it not only provides practical solutions for critical clinical needs but also offers new avenues for the advancement of drug delivery technologies.

The Self-Emulsifying Drug Delivery System (SEDDS) Platform for Poorly Water-Soluble Injectable Drugs utilizes specialized formulations to create non-aqueous homogeneous systems, disrupting traditional emulsification technologies. This platform allows for pre-use preparation, features a simple manufacturing process and excellent stability, and enables high efficacy with low toxicity. Currently, multiple products based on this technology have entered clinical trials or are in the production application stage.

The oral nanodelivery platform for poorly soluble drugs employs a globally pioneering nano-scaffold technology, leveraging the nanostructure and bioadhesive properties of pharmaceutical excipients to enhance the bioavailability of poorly soluble drugs. Currently, multiple products have completed preclinical studies or entered clinical trials.

It is worth noting that national new drugs developed based on two major technology platforms can comprehensively overcome and improve the defects or deficiencies of existing drugs, achieving significant improvements in multiple dimensions such as efficacy, safety, and clinical compliance, thereby serving as effective substitutes for current medications.

National policies and regulations provide support for innovative drug delivery systems. Leveraging its unique technology platform and exceptional commercial capabilities, Beijing Delifurui Pharmaceutical Technology Co., Ltd. is poised to accelerate the market launch of its new drugs, shorten R&D cycles, reduce development costs, and significantly enhance the market competitiveness of its products.

In the pharmaceutical sector, technological breakthroughs are often accompanied by lengthy R&D cycles and high costs of trial and error. Delifurui’s ability to achieve multiple “global firsts” is inextricably linked to the technical expertise accumulated by its core team.

Delifurui’s innovative technologies originated from the team of Academician Zhang Qiang at Peking University. Professor Zhang Qiang, an academician of the Chinese Academy of Engineering and a Boya Distinguished Chair Professor at Peking University, has long held key academic positions in the Professional Committee on Pharmaceutical Preparations and the Professional Committee on Nanomedicines, and is a renowned scholar in the field of pharmaceutics in China. With ten years of extensive experience in the industry, he possesses rich expertise in basic research and industrialization, as well as resources for new drug review and internationalization. Co-founders Dr. Wu Cuishuan and Mr. Ma Fengzhong have demonstrated exceptional capabilities in pharmaceutical R&D and commercial operations, respectively.

As one of the leading figures in the field of pharmaceutics in China, Academician Zhang Qiang’s team possesses end-to-end capabilities spanning academic research and industrial translation, providing a unique advantage for the rapid implementation of technologies. It is precisely this “academia + industry” dual-drive model that has become the key to the rapid rise of Beijing Delifurui Pharmaceutical Technology Co., Ltd.

Supported by its team, Delifurui received support from the inaugural Chinese Pharmaceutical Association–Yiling Biomedical Innovation Fund in 2015; won the Second Prize of the National Science and Technology Progress Award (Injection Delivery Technology) in 2019; was selected for the Zhongguancun Disruptive Technology R&D and Industrialization Support Project in 2020; received the AI+Health Collaborative Innovation Incubation Project from the Beijing Municipal Science and Technology Commission and the Excellence Award at the 2021 National Disruptive Technology Competition organized by the Ministry of Science and Technology in 2021; and obtained support for the Disruptive Technology Innovation Project from the Ministry of Science and Technology (Oral Delivery Technology) in 2023.

Moreover, Delifurui has secured investments from multiple industry-leading enterprises, including China Resources Group (a Fortune Global 100 company), the Beijing-Tianjin-Hebei National Technology Innovation Center (the nation’s first comprehensive technology innovation center), and Beijing Sihuan Kebao Pharmaceutical Co., Ltd. The participation of these investors has not only provided financial support to Delifurui but also brought abundant industry resources and market channels, laying a solid foundation for its future development.

This financing round not only affirms Delifurui’s long-standing commitment to innovation and technological leadership, but also serves as a significant boost to the company’s future development. The infusion of capital will further advance the company’s R&D efforts, accelerate product commercialization, and facilitate subsequent iterative updates, thereby meeting growing market demand.

Sun Zhengzheng, Deputy General Manager of HY Asset Management Co., Ltd., stated: Biopharmaceuticals is one of the core sectors in which HY Asset Management Co., Ltd. has deeply cultivated. We have always focused on innovative enterprises with breakthrough technologies that can effectively address clinical pain points. Leveraging its globally pioneering drug delivery technology platform, the team at Beijing Delifurui Pharmaceutical Technology Co., Ltd. has achieved disruptive breakthroughs in the fields of injectable and oral formulations. With high technological barriers and a clear path for clinical translation, its technology aligns perfectly with the national strategic direction of "overcoming bottleneck technologies." We place particular emphasis on its unique business model, which accelerates product commercialization through formulation innovation during the window of favorable policy support, as well as the full-chain capabilities spanning academic research and industrial translation demonstrated by Academician Zhang Qiang’s team and Beijing Delifurui. In the future, we will leverage the ecosystem resources of HY Asset Management Co., Ltd. and collaborate with strategic partners such as the National Innovation Center for Beijing-Tianjin-Hebei Region to help Beijing Delifurui grow into a benchmark enterprise in the global drug delivery field.

Beijing Delifurui Pharmaceutical Technology Co., Ltd statedThe success of this financing round not only recognizes Delifurui’s efforts over the past years but also reflects high expectations for its future development, marking a solid step forward in the field of innovative drug delivery systems. Delifurui will continue to uphold the spirit of innovation, strengthen technological R&D and market expansion, and enhance its core competitiveness, thereby making greater contributions to the independent innovation and industrialization of China’s drug delivery systems. Meanwhile, we look forward to more partners joining us in innovation to jointly promote the innovation and development of China’s pharmaceutical industry.

Since the inception of modern medicine, drug delivery has remained a consistent and central topic of interest. In recent years, with the advancement of emerging fields such as nucleic acid therapeutics and gene editing therapies, delivery systems have played an increasingly critical role in new drug development and commercialization. They have demonstrated significant market potential and broad application prospects in areas including biologics, gene therapy, and traditional Chinese medicine formulations.

As Delifurui continues to refine its product portfolio and intensify its marketing efforts, the company is poised to deliver more breakthrough achievements in the field of drug delivery. In doing so, it will not only advance drug delivery technologies but also better meet clinical and patient needs, thereby contributing to the progress of the global pharmaceutical industry.

As a shareholder of Tianjin Haihe Industry Fund Management Co., Ltd., the manager of the Tianjin Municipal Government Guidance Fund, HY Capital holds a seat on its board of directors. Leveraging this position, it has established multiple industry funds, including the Zhongke Haihe Biopharmaceutical Industry Fund, the Brain-Computer Interface HY Haihe Haitai Venture Capital Fund, and the Huailai Big Data Fund. Guided by the core philosophy of “professional focus and win-win cooperation,” and adhering to the mission of “discovering and supporting China’s outstanding technology enterprises to grow alongside them,” HY Capital focuses on investment opportunities in brain science and neuromorphic intelligence, biopharmaceuticals, medical devices, and synthetic biology.